Lundbeck in CNS alliance with Otsuka Pharmaceutical
H. Lundbeck A/S is to pay $200 million upfront to Otsuka Pharmaceutical Co Ltd of Japan as part of an alliance that will give it access to two late clinical stage CNS compounds including a new formulation of the antidepressant, aripiprazole.